Clinical Review

Biosimilars in Psoriasis: The Future or Not?

Author and Disclosure Information

 

References

Economic Advantages of Biosimilars

The annual economic burden of psoriasis in the United States is substantial, with estimates between $35.2 billion22 and $112 billion.23 Biosimilars can be 25% to 30% cheaper than their reference products9,11,24 and have the potential to save the US health care system billions of dollars.25 Furthermore, the developers of biosimilars could offer patient assistance programs.11 That being said, drug developers can extend patents for their branded drugs; for instance, 2 patents for Enbrel (Amgen Inc) could protect the drug until 2029.26,27

Although cost is an important factor in deciding which medications to prescribe for patients, it should never take precedence over safety and efficacy. Manufacturers can develop new drugs with greater efficacy, fewer side effects, or more convenient dosing schedules,26,27 or they could offer co-payment assistance programs.26,28 Physicians also must consider how the biosimilars will be integrated into drug formularies. Would patients be required to use a biosimilar before a branded drug?11,29 Will patients already taking a branded drug be grandfathered in?11 Would they have to pay a premium to continue taking their drug? And finally, could changes in formularies and employer-payer relationships destabilize patient regimens?30

Conclusion

Preliminary results suggest that biosimilars can have similar safety, efficacy, and immunogenicity data compared to their reference products.19,21 Biosimilars have the potential to greatly reduce the cost burden associated with psoriasis. However, how similar is “highly similar”? Although cost is an important consideration in selecting drug therapies, the reason for using a biosimilar should never be based on cost alone.

Pages

Recommended Reading

MTX side effects limit patient use
MDedge Dermatology
VIDEO: Interchangeability of biosimilars and parent compounds raise potential efficacy issues
MDedge Dermatology
VIDEO: Adding methotrexate to a biologic may help achieve treatment goal
MDedge Dermatology
The Role of Biologic Therapy for Psoriasis in Cardiovascular Risk Reduction
MDedge Dermatology
VIDEO: Pediatric psoriasis patients prepare for biologics
MDedge Dermatology
New Biologics in Psoriasis: An Update on IL-23 and IL-17 Inhibitors
MDedge Dermatology
Cost of Diagnosing Psoriasis and Rosacea for Dermatologists Versus Primary Care Physicians
MDedge Dermatology
Clinical Pearl: Early Diagnosis of Nail Psoriasis and Psoriatic Arthritis
MDedge Dermatology
VIDEO: Distinctive features define pediatric psoriasis
MDedge Dermatology
VIDEO: Coffee break at the Hawaii Dermatology Seminar
MDedge Dermatology

Related Articles